Bayer AG (BAYZF.PK)

BAYZF.PK on OTC Markets Group

130.60USD
22 Aug 2014
Price Change (% chg)

$-0.84 (-0.64%)
Prev Close
$131.44
Open
$130.86
Day's High
$131.25
Day's Low
$130.60
Volume
3,107
Avg. Vol
676
52-wk High
$145.00
52-wk Low
$108.85

BAYZF.PK

Chart for BAYZF.PK

About

Bayer AG is a German holding company active in the field of health care, nutrition and high-tech materials. It has three business subgroups: HealthCare, involved in the research, development and manufacture of health products for people and animals, CropScience, engaged in the crop protection and non-agricultural pest control,... (more)

Overall

Beta: 0.92
Market Cap (Mil.): €85,051.59
Shares Outstanding (Mil.): 826.95
Dividend: 2.10
Yield (%): 2.04

Financials

  BAYZF.PK Industry Sector
P/E (TTM): 23.86 32.67 33.58
EPS (TTM): 4.31 -- --
ROI: 9.08 18.00 17.30
ROE: 18.35 18.64 18.05
Search Stocks

Fitch Assigns Bayer AG's Hybrid Notes 'BBB+', 50% Equity Credit; Affirms IDR at 'A'

(The following statement was released by the rating agency) LONDON, August 13 (Fitch) Fitch Ratings has assigned Bayer AG's EUR1.75bn and EUR1.5bn subordinated resettable floating-rate notes a rating of 'BBB+', two notches below Bayer's Issuer Default Rating (IDR) of 'A' in line with the existing hybrid notes. Fitch has applied a 50% equity credit to the two bonds, which are identical in ranking and terms with exception of maturity and pricing. Fitch has also affirmed Bayer's IDR at 'A' wit

13 Aug 2014

BRIEF-Bayer receives EU approval for Eylea in diabetic macular edema

Aug 11 - Bayer AG : * Says receives EU approval for Eylea in diabetic macular edema * Says plans for an immediate roll-out with Germany being one of the first

11 Aug 2014

Bayer says discussing size of animal health unit

FRANKFURT, July 30 - German healthcare group Bayer is discussing internally whether its animal health unit needs to be bulked up to better compete with rivals, its chief executive said.

30 Jul 2014

UPDATE 2-Bayer's new drug boost dampened by strong euro

* Sees 41 bln euros in 2014 sales vs 41-42 bln previously

30 Jul 2014

BRIEF-Bayer's Regorafenib wins EU approval for treatment of gastrointestinal tumors

July 30 - Bayer AG : * Says regorafenib (Stivarga) approved in the European union for the treatment of gastrointestinal stromal tumors Source text: http://bit.ly/1oJQTkj

30 Jul 2014

BRIEF-Bayer's Eylea receives FDA approval for the treatment of diabetic macular edema

July 30 - Bayer AG : * Says Eylea receives FDA approval for the treatment of diabetic macular edema

30 Jul 2014

German stocks - Factors to watch on July 30

FRANKFURT, July 30 - The DAX top-30 index looked set to open 0.1 percent lower on Wednesday, according to premarket data from brokerage Lang & Schwarz at 0603 GMT.

30 Jul 2014

Bayer Q2 underlying profit edges higher on new drug sales

FRANKFURT, July 30 - Bayer, Germany's largest drugmaker, posted a 1 percent gain in quarterly adjusted core earnings, as strong sales growth of newly introduced pharmaceuticals was tempered by a strong euro weighing on the value of overseas sales.

30 Jul 2014

UPDATE 1-Drug maker Orion's Q2 profit rises on Bayer, Takeda payments

* Result boosted by one-off payments from Bayer and Takeda

29 Jul 2014

Drug maker Orion's Q2 profit rises on Bayer payments

HELSINKI, July 29 - Finnish drug maker Orion reported its second-quarter operating profit rose 41 percent from a year ago, boosted by upfront payments from Germany's Bayer.

29 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks